PLAUR and neoplasm: Tumor specific binding of activator protein (AP-1) to uPAR promoter has been detected in ~40% CRC patients, and 39.8% of them showed this tumor specific binding in the resected tumors in contrast to low or absent binding in corresponding normal mucosa [76] demonstrating the tumor specific activity of uPAR in CRC and not in normal tissue.